AREVA Med Inaugurates Second Lead-212 Production Facility
PLANO, Texas, 2016-04-13 21:39 CEST (GLOBE NEWSWIRE) -- AREVA Med has launched operations at its second high-purity lead-212 (212Pb) production facility located in Plano, Texas. Known as the DDPU (Domestic Distribution and Purification Unit), this facility was officially opened today in the presence of local elected officials, AREVA Med Scientific Advisory Committee, as well as AREVA Group and AREVA Med executives and teams from both the U.S. and France.
A photo accompanying this release is available athttp://www.globenewswire.com/NewsRoom/AttachmentNg/bccb050d-dfc0-46c3-9964-a31bc2f553f4
Thanks to its unique characteristics, lead-212 is used in targeted alpha therapy (TAT), in an increasing number of promising and innovative studies to target cancer cells, while limiting the impact on nearby healthy cells.
In a centralized modular plant, the DDPU will hold all AREVA Med’s U.S. activities and those of its subsidiary Macrocyclics, the global leader in the design and manufacturing of chelating agents for nuclear medicine. With brand new equipment, this state-of-the-art facility is a unique opportunity for AREVA Med to expand the range and increase the quality of products and services for its American partners and customers. Thanks to this increased production capacities, AREVA Med will accelerate the development of innovative Targeted Alpha Therapies using lead-212 to combat cancer.
Harry LaRosiliere, the mayor of Plano, declared: “It is always a great day when we can welcome to the City of Plano a U.S. Headquarters and international company such as AREVA Med, which does invaluable work in the field of cancer research. We look forward to their success and future expansion as they continue to develop innovative cancer therapies.”
Patrick Bourdet, AREVA Med’s CEO added:“Our new modular and unique U.S. plant will allow us to quickly expand our cancer therapy pipeline and increase collaboration within the entire continent.”
More about AREVA Med
AREVA Med is the AREVA Group medical subsidiary formed in 2009 to develop new therapies to fight cancer. AREVA Med has developed a unique process to extract lead-212 (212Pb), a rare metal used in targeted alpha therapy (TAT), a novel approach which targets and destroys cancer cells, while limiting the impact on nearby healthy cells. AREVA Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform.
Harry LaRosiliere, mayor of Plano; Patrick Bourdet, AREVA Med CEO photo credit: Jim Herndon
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
GlobeNewswire, Inc.21.11.2018 19:54 | Pressemeddelelse
This is a test from GlobeNewswire
Patton Electronics Co.20.11.2018 13:16 | Pressemeddelelse
Patton Delivers IPv6 Services at the Network Edge
Lantronix, Inc.19.11.2018 22:17 | Pressemeddelelse
Lantronix to Present at the 11th Annual LD Micro Main Event on December 5, 2018
Bombardier Transportation19.11.2018 15:32 | Pressemeddelelse
Bombardier to supply 19 OMNEO Premium trains for the Hauts-de-France region’s intercity lines
Invivoscribe, Inc.19.11.2018 14:01 | Pressemeddelelse
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
BlissCo Cannabis Corp.16.11.2018 14:01 | Pressemeddelelse
BlissCo Receives Cannabis Sales License from Health Canada
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum